NL-OMON36726已完成不适用
A One-Way Drug-Drug Interaction Study to Assess the Effect of Ritonavir-boosted Atazanavir on the Pharmacokinetics, Safety and Tolerability of BMS-790052 in Healthy Subjects - BMS-790052/ritonavir-boosted atazanavir drug-drug interaction study
Bristol-Myers Squibb0 个研究点目标入组 14 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Age: 18-49 years, inclusive
- •BMI: 18.0 - 32.0 kg/m2, inclusive
- •Women of child bearing potential should use adequate contraception (e.g., double barrier method) until at least 4 weeks after last dose of study medication
排除标准
- •- Any significant acute or chronic medical illness.
- •- Current or recent (within 3 months of study drug administration) gastrointestinal disease indicated as clinically relevant by the Medical Investigator.
- •- Any major surgery within 4 weeks of study drug administration.
- •- Any gastrointestinal surgery that could impact upon the absorption of study drug.
- •- Donation of blood or plasma to a blood bank or in a clinical study (except a screening visit) within 90 days of study drug administration.
- •- Blood transfusion within 90 days of study drug administration.
- •- Inability to tolerate oral medication.
- •- Inability to swallow oral medication in the form of tablets or capsules.
- •- Inability to be venipunctured and/or tolerate venous access.
- •- Smoking more than 5 cigarettes per day.
- •- Recent (within 6 months of study drug administration) drug or alcohol abuse as defined in DSM IV, Diagnostic Criteria for Drug and Alcohol Abuse (see Appendix 1).
- •- History of cardiac conduction abnormalities.
- •- History of nephrolithiasis.
- •- Any other sound medical, psychiatric and/or social reason as determined by the investigator.
- •- Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population.
- •- Positive urine screen for drugs of abuse.
- •- Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, HIV viral load, or HIV-1, -2 antibody
- •- History of any significant drug allergy (such as Stevens-Johnson Syndrome, anaphylaxis or hepatotoxicity).
- •- Pregnancy or lactation (females only).
- •- Prisoners or subjects who are involuntarily incarcerated.
- •- Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease)
研究者
相似试验
已完成
不适用
A ONE-WAY DRUG DRUG INTERACTION STUDY TO ASSESS THE EFFECT OF EFAVIRENZ ON THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF BMS-790052 IN HEALTHY SUBJECTSviral liver inflammation10047438Hepatitis CNL-OMON36747Bristol-Myers Squibb17
尚未招募
1 期
A Phase 1 Drug-Drug Interaction Study to Assess the Interaction Potential of NB-4746 on CYP1A2 and CYP3A4 Substrates in Healthy VolunteersACTRN12624001072505ura Bio18
尚未招募
不适用
A phase 1 study to evaluate drug-drug interactions of Bojungikgitang with Clopidogrel, Atorvastatin, and Fimasartan/Amlodipine in healthy adult volunteersKCT0007296Kyunghee University-industry Cooperation Foundation42
已完成
不适用
A Drug-Drug Interaction, Safety and Efficacy Study With JNJ-56021927 (ARN-509) and Abiraterone Acetate in Subjects With Metastatic Castration-Resistant Prostate Cancer10036958prostate cancerNL-OMON44408Johnson & Johnson Pharmaceutical10
已完成
不适用
A study to assess pharmacokinetic interactions by evaluating the effect of red ginseng in healthy Korean adultsSymptoms, signs and abnormal clinical and laboratory findings, NECKCT0002418Kyungpook National University Hospital15